BRIEF—Daiichi Sankyo launches oncolytic virus as treatment for malignant glioma in Japan

Japanese drugmaker Daiichi Sankyo has launched Delytact (teserpaturev/G47∆) in its home country to treat a type of brain cancer.

Delytact is an oncolytic virus developed by the company in collaboration with Tomoki Todo of the Institute of Medical Science, The University of Tokyo.

It received conditional and time-limited marketing approval in Japan as a regenerative medical product for treatment of malignant glioma in June 2021 based on results from a Japanese Phase II trial in glioblastoma conducted by Professor Todo.

For the time being, Delytact will be commercially available only at hospitals that served as trial sites. Daiichi Sankyo says that it will establish a stable supply system of the medicine as soon as possible.